|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Atrasentan>> Market Analysis Reports |
Market Analysis Reports of Atrasentan |
|
Atrasentan hydrochloride (CAS 195733-43-8) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Atrasentan hydrochloride Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Atrasentan (CAS 173937-91-2) December 2024 Global Market Report of Atrasentan hydrochloride (CAS 195733-43-8) December 2024 CAS 173937-91-2 Atrasentan Chemical Report & Database ... Report & Database definitions: Name: Atrasentan: Atrasentan; (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine ... : Chemical or Reaction Intermediate The Atrasentan Report & Database gives Market Consumption ... CAS 195733-43-8 Atrasentan hydrochloride Chemical Report & Database ... Report & Database definitions: Name: Atrasentan hydrochloride: Atrasentan-hydrochloride; (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl ... : Chemical or Reaction Intermediate The Atrasentan hydrochloride Report & Database gives Market ... IgA Nephropathy- Pipeline Insight, 2021 ... IgA Nephropathy Emerging Drugs Atrasentan: Chinook Therapeutics Atrasentan is a potent and selective ... initiate a phase 3 trial (ALIGN) of Atrasentan in early 2021 in patients with ... Pharmaceuticals, Inc. Key Products Atrasentan LNP023 Nefecon Sparsentan BION ... Endothelin Receptor Antagonist - Pipeline Insight, 2022 ... the treatment of Resistant hypertension. Atrasentan: Chinook Therapeutics Atrasentan is a highly potent and selective ... Pharmazz Key Products Aprocitentan Sparsentan Atrasentan Bosentan Macitentan Getagozumab Ambrisentan Sovateltide ... Global IgA Nephropathy Treatment Market - 2025-2033 ... accelerated approval for Vanrafia (atrasentan), developed by Novartis AG. Atrasentan is a novel first-in-class drug ... Type2 Diabetes Mellitus- Pipeline Insight, 2022 ... /Metoprolol Ruboxistaurin Mesylate BMS-816336 Atrasentan Inhaled Human Insulin Human regular ... Alport Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major Alport syndrome markets are expected to exhibit a CAGR of 3.46% during 2024-2034. The Alport syndrome market has been comprehensively analyzed in IMARC's new report titled "Alport Syndrome Market: Epidemiology, Industry Trends, Share, Size, ... Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major focal segmental glomerulosclerosis markets reached a value of US$ 332.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 578.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2024-2034. The focal ... IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035 ... accelerated approval for Novartis’ Vanrafia (atrasentan) for the treatment of primary immunoglobulin ... Piperonal Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type ... of Tadalafil, Stiripentol, Droxidopa, L-Dopa, and Atrasentan, among other important medications. This ... |